The 3% convertible senior notes are due 2029

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by Merit Medical Systems, Inc. of an aggregate principal amount of $747.5 million of its 3.00% convertible senior notes due 2029. Davis Polk also advised the counterparties to capped call transactions entered into by Merit in connection with the offering. Merit intends to use the net proceeds of the offering to pay the cost of the capped call transactions and for general corporate purposes.

Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Merit is determined to make a difference by understanding its customers’ needs and innovating and delivering a diverse range of products that improve the lives of people and communities throughout the world.

The Davis Polk corporate team included partner Yasin Keshvargar and associate Steven Glendon. The equity derivatives team included partner Mark M. Mendez and associates Greg Marchesini and Lindsey B. Meyers-Perez. The tax team included partner Michael Farber, counsel Aliza Slansky and associate William Liang. The intellectual property team included partner David R. Bauer and associate Gabrielle Mazero. All members of the Davis Polk team are based the New York office.